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Pigment epithelium-derived factor (PEDF) is a potent multifunctional protein that inhibits angiogenesis and has neurogenic and
neuroprotective properties. Since thewet formof age-relatedmacular degeneration is characterized by choroidal neovascularization
(CNV), PEDF would be an ideal candidate to inhibit CNV and support retinal pigment epithelial (RPE) cells. However, its short
half-life has precluded its clinical use. To deliver PEDF to the subretinal space, we transfected RPE cells with the PEDF gene using
the Sleeping Beauty transposon system. Transfected cells expressed and secreted biologically active recombinant PEDF (rPEDF).
In cultures of human umbilical vein endothelial cells, rPEDF reduced VEGF-induced cumulative sprouting by ≥47%, decreased
migration by 77%, and increased rate of apoptosis at least 3.4 times. rPEDF induced neurite outgrowth in neuroblastoma cells and
protected ganglion and photoreceptor cells in organotypic retinal cultures. In a rat model of CNV, subretinal transplantation of
PEDF-transfected cells led to a reduction of the CNV area by 48% 14 days after transplantation and decreased clinical significant
lesions by 55% and 40% after 7 and 14 days, respectively. We showed that transplantation of pigment epithelial cells overexpressing
PEDF can restore a permissive subretinal environment for RPE and photoreceptor maintenance, while inhibiting choroidal blood
vessel growth.
1. Introduction
The avascularity of the outer retina is essential to maintain a
proper neurogenic environment for the photoreceptors and
retinal neurons, which could be harmed by changes in the
composition of blood, such as an excess of glutamate [1].
Retinal pigment epithelial (RPE) cells form a tight monolayer
at the interface between the neural retina and the choroid
and prevent the choroidal vasculature from invading the
subretinal space and the outer retina. RPE cells are important
in maintaining the angiogenic homeostasis of the outer
retina by synthesizing and secreting angioregulatory proteins,
including the proangiogenic vascular endothelial growth fac-
tor (VEGF) [2, 3] and the antiangiogenic pigment epithelium-
derived factor (PEDF) [4–6]. Even though other factors, such
as fibroblast growth factor and transforming growth factor-
beta [7], endostatin [8, 9], and thrombospondin-1 [6, 10],
contribute, it is the equilibrium between VEGF and PEDF
that is most responsible for maintaining the outer retina
avascular [11, 12]. It is the imbalance in proangiogenic and
antiangiogenic factors that has been implicated in a number
of severe ocular diseases, such as neovascular age-related
macular degeneration (AMD), diabetic retinopathy, sickle
cell retinopathy, and retinopathy of prematurity [13–16]. Even
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though neovascularization is a complex event that requires
endothelial cell proliferation, migration, and tissue degrada-
tion, it has been assumed that inhibition of VEGF is sufficient
to inhibit choroidal neovascularization (CNV). Based on
this assumption, inhibitors of VEGF have been developed
and successfully used to control neovascularization under
pathological conditions, such as cancer [17], macular edema
[18], retinopathy of prematurity [19], and neovascular AMD
[20, 21].
The first VEGF inhibitor approved for ocular use, specifi-
cally for the treatment of neovascular AMD, was pegaptanib,
a synthetic PEGylated oligonucleotide that binds the VEGF-
A
165
isoform. However, its effectiveness as a treatment of
neovascular AMD was minimal [22]. In 2006, the Food and
Drug Administration (FDA) approved ranibizumab (Lucen-
tis, Novartis Pharma GmbH), a humanized Fab fragment
derived from the parent monoclonal antibody bevacizumab
(Avastin, Roche), for intraocular use to treat neovascular
AMD. Intravitreal injection of ranibizumab controls CNV
in 90% of patients with significant vision improvement in
30–40% of patients [23, 24]. In addition to ranibizumab, the
parent monoclonal antibody bevacizumab and the recom-
binant fusion protein aflibercept (Eylea, Bayer HealthCare)
are also used for the treatment of neovascular AMD [20, 21].
Since the intravitreal half-life of these drugs is short, patients
need frequent, often monthly injections for life to reduce the
leakage from CNV. The logistic of the frequent intravitreal
injections, especially in the older patient, often results in the
patient discontinuing treatment. Intravitreal injections have
also been linked to local side effects, such as endophthalmitis,
ocular hypertension [25], submacular hemorrhage [26], and
rarely occurring thromboembolic events [27].
The replacement of damaged RPE by subretinal trans-
plantation of autologous RPE or iris pigment epithelial (IPE)
cells in neovascular AMDpatients [28, 29] has not shown any
significant improvement in functional outcome.We hypothe-
size that subretinal transplantation of pigment epithelial cells
that secrete therapeutic levels of PEDF continuously for the
life of the patient will inhibit and induce regression of CNV
without local and systemic side effects. In fact, a number of
investigators have reported that the subconjunctival injection
of recombinant PEDF (rPEDF) [30] and the intravitreal or
subretinal administration of viral vectors encoding the PEDF
gene control ocular neovascularization [31, 32]. However,
injection of PEDF protein to control CNV is not feasible
since it has a short half-life [33] and would require frequent
injections. Administration of viral vectors encoding the
PEDF gene is an option to control CNV, although viral
vectors may have a number of limitations that preclude their
clinical use, mostly related to their immunogenicity [34–36].
Ocular gene therapies using adenoviral and adenoassociated
viral vectors have been used in clinical trials with success.
However, some patients have shown mild to moderate
local as well as systemic adverse-event profiles [37–39]. In
2006, phase I clinical trial including patients with advanced
neovascular AMD showed that high doses of intravitreally
injected adenoviral vectors expressing human PEDF led to
antiangiogenic activity lasting several months [40]. However,
no follow-up clinical trial has been reported.
To avoid the side effects associated with virally mediated
gene delivery, we have used the hyperactive Sleeping Beauty
(SB100X) transposon system to transfect pigment epithelial
cells with the PEDF gene [41]. SB100X has a number of
advantages over virally mediated gene delivery: it integrates
transgenes exclusively into TA dinucleotides with specific
predilection for dinucleotides that have distinct structural
features, integrates transgenes with high efficiency, results
in stable integration, integrates large inserts, and does not
primarily integrate into transcriptional sequences [42–45].
This study was designed to investigate whether the
SB100X transposon system can efficiently transfect primary
pigment epithelial cells with the human PEDF gene and
whether the secreted rPEDF is functional as an inhibitor of
VEGF-mediated endothelial cell function and as a neuropro-
tective agent in vitro and whether PEDF-transfected pigment
epithelial cells have the potential to inhibit neovascularization
in vivo in a model of CNV.
2. Materials and Methods
2.1. Cell Culture. Human umbilical vein endothelial cells
(HUVEC) were isolated as described by Korff and Augustin
[46] and cultured in endothelial cell growth (ECG) medium,
containing 0.02mL/mL fetal calf serum, 0.004mL/mL
endothelial cell growth supplement, 0.1 ng/mL recombinant
human epidermal growth factor, 1 ng/mL recombinant
human basic fibroblast growth factor, 90𝜇g/mL heparin, and
1 𝜇g/mL hydrocortisone (PromoCell, Heidelberg, Germany),
and supplemented with 80U/mL penicillin, 80𝜇g/mL
streptomycin (Lonza, Basel, Switzerland), and 2.5𝜇g/mL
amphotericin B (Sigma-Aldrich Chemie, Taufkirchen,
Germany). Rat RPE cells were isolated from Long Evans
rats as described previously [41]. Briefly, eyes were cut
circumferentially below the ora serrata, the neural retina
was removed, and the eye cup was filled with 0.05% trypsin
(PAA Laboratories, Pasching, Austria). After 10 minutes, the
RPE cells were dislodged by trituration. An equal volume of
Dulbecco’s Modified Eagle’s Medium (DMEM)/Ham’s F-12
(Biochrom AG, Berlin, Germany) supplemented with 10%
fetal bovine serum (FBS, PAA Laboratories) was added to the
trypsin-cell mixture and centrifuged at 1000 rpm for 5 min-
utes.TheRPE cell pellet was suspended inDMEM/Ham’s F-12
supplemented with 10% FBS, 80U/mL penicillin, 80 𝜇g/mL
streptomycin, and 2.5 𝜇g/mL amphotericin B and plated into
tissue culture dishes. Second passage cells were immortalized
by transfection with pSV3-neo plasmid. Immortalized
cells were maintained in DMEM/Ham’s-F-12 supplemented
with 10% FBS, 80U/mL penicillin, 80𝜇g/mL streptomycin,
and 2.5 𝜇g/mL amphotericin B at 37∘C in a humidified
atmosphere of 95% air and 5% CO
2
. Medium was changed
twice a week and cells were passaged every 10 days. ARPE-19
cells (ATCC CRL-2302) were maintained and passaged
weekly according to the depositors recommendations.
2.2. Culture and Transfection of RPE Cells with the PEDF
Gene. Construction of the PEDF transposon plasmid, whose
expression cassette contains the His-tag fused human PEDF
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gene flanked by inverted repeat/direct repeat regions, and
transfection using the SB100X transposon system have been
reported previously [41]. Briefly, RPE cells were electropo-
rated with the Neon Transfection System using the 10 𝜇L Kit
(Invitrogen, Carlsbad, CA). 105 cells in 11 𝜇L resuspension
buffer R (Invitrogen) were added to 0.5𝜇g plasmid mixture,
containing the SB100X transposase plasmid and the PEDF
transposon plasmid at a ratio of 1 : 16. Electroporation was
carried out using 1350V (pulse voltage), 20ms (pulse width),
and 2 pulses. After transfection, ARPE-19 and immortalized
rat RPE cells were transferred into 12-well tissue culture plates
in 2mL DMEM/Ham’s F-12 media supplemented with 10%
FBS without antibiotics. Antibiotics were added with the first
mediumchange 3 days after transfectionwhen the transfected
cells were transferred into 75 cm2 cell culture flasks and the
media were analyzed for rPEDF secretion. Established rat
RPE and transfected ARPE-19 cells were passaged weekly.
2.3. Purification and Analysis of rPEDF Secreted into Culture
Media. Recombinant PEDFwas purified usingNi-NTA resin
(Qiagen, Hilden, Germany) according to the manufacturer’s
instructions. Briefly, cell culture media from PEDF-
transfected cells were collected, clarified by centrifugation
for 10 minutes at 1000 rpm at 4∘C, mixed with one-third
volume of 4x incubation buffer (200mMNaH
2
PO
4
, pH 8.0,
1.2MNaCl, and 40mM imidazole), and applied to Ni-NTA
resin. After washing the resin twice with 1x incubation buffer,
the bound protein was eluted with the appropriate volume of
elution buffer (50mMNaH
2
PO
4
, pH 8.0, 300mMNaCl, and
250mM imidazole). Purified rPEDF was equilibrated with
PBS, concentrated on Microcon columns (Merck Millipore,
Billerica, MA), sterile-filtered, and stored in aliquots at 4∘C
until use.
2.4. Quantification of rPEDF in Rat Eyes. Quantification
of rPEDF in rat eyes after cell transplantation was carried
out by homogenization of the whole eye and incubation of
the homogenate with 100 𝜇L of radioimmunoprecipitation
assay (RIPA) buffer (Pierce Biotechnology, Rockford, IL).
RIPA-extracted homogenates were separated on a 10%
SDS-polyacrylamide gel. For Western blot analysis, proteins
were transferred onto a 0.45 𝜇m pore size nitrocellulose
membrane (Whatman, Maidstone, Kent, UK). Blots, blocked
with 3% BSA/TRIS-buffered saline (TBS) overnight at
4∘C, were incubated with anti-PEDF antibodies (rabbit
polyclonal, 1 : 4000; BioProducts MD, Middletown, MD)
diluted in 3% BSA/TBS at room temperature. After 2 hours,
blots were incubated for 1 hour at room temperature with
horseradish peroxidase-conjugated anti-rabbit antibodies
(goat polyclonal, 1 : 2000; Abcam, Cambridge, United
Kingdom) diluted in 10% milk powder/TBS. Protein bands
were visualized by chemiluminescence using the LAS-3000
imaging system (FujiFilm, Tokyo, Japan). ELISA-based
quantification was performed using the ELISAquant kit
for human PEDF (BioProducts MD) and Ni-NTA HisSorb
plates (Qiagen) according to the manufacturer’s instructions.
2.5. Neurite Outgrowth. Human neuroblastoma SH-SY5Y
cells (CLS Cell Lines Service GmbH, Eppelheim, Germany)
were used to examine the effects of rPEDF on neurite out-
growth. SH-SY5Y cells were seeded in 24-well culture plates
at a density of 5× 103 cells/cm2. After the cells were adapted to
serum-free DMEM/Ham’s F-12 for 24 hours, affinity-purified
rPEDF was added at 20 and 100 ng/mL for a period of 5 days.
Control cells were maintained in serum-free medium alone.
Neurite outgrowth was visualized in living cultures by phase
contrast microscopy. For each treatment, 6microscopic fields
were imaged and the total neurite length was measured using
the ImageJ software (National Institutes of Health, Bethesda,
MD) [47]. Total neurite length was related to the total area of
cell bodies as a parameter proportional to cell number.
2.6. Organotypic Retinal Culture. Cultures of bovine neural
retinas were prepared as previously described [48, 49] and
cultivated in the absence or presence of 100 ng/mL purified
rPEDF for a period of 72 hours. Tissues were analyzed by
hematoxylin/eosin staining or processed for immunohisto-
chemistry and compared to sections of freshly isolated reti-
nas. Staining of photoreceptor cell outer segmentswas carried
out with anti-rhodopsin antibodies (mouse monoclonal,
clone 1D4, 1 : 500; Sigma-Aldrich, Taufkirchen, Germany);
nuclear staining was performed using DAPI (Roche Applied
Science, Mannheim, Germany).
2.7. Spheroid-Based Angiogenesis Assay. Endothelial cell
spheroids of defined cell numbers were generated as
described by Korff and Augustin [46]. Briefly, HUVEC
were suspended in ECG medium containing 20% (w/v)
carboxymethyl cellulose (Sigma-Aldrich) and seeded in 25𝜇L
drops containing 400 cells on nonadherent plastic Petri
dishes (Greiner Bio-One GmbH, Frickenhausen, Germany).
Under these conditions, all suspended cells contribute to
the formation of a single spheroid per drop. After overnight
incubation at 37∘C in a humidified atmosphere of 95% air
and 5% CO
2
, the spheroids were embedded into collagen
gels and rapidly transferred into prewarmed 24-well tissue
culture plates. After 30 minutes at 37∘C to allow the collagen
to polymerize, 100 𝜇L of endothelial basal medium, medium
containing 20 ng/mL VEGF with and without the addition of
purified rPEDF at concentrations of 20, 100, and 200 ng/mL,
and bevacizumab at concentrations of 50, 250, and 500𝜇g/mL
were layered on top of the gels. After 24 hours, capillary
sprouting was quantified bymeasuring the cumulative length
of sprouts using the digital imaging software ImageJ.
2.8. TUNEL Assay. The effect of VEGF, rPEDF, and beva-
cizumab on HUVEC apoptosis was analyzed using TUNEL
staining (In Situ Cell DeathDetectionKit, Fluorescein, Roche
Applied Science) according to the manufacturer’s protocol.
2.9. Migration Assay. HUVEC were plated in complete ECG
medium in the upper chamber of an 8 𝜇m pore size tran-
swell insert. After 4 hours at 37∘C to allow the cells to
attach, the media were replaced with minimal ECG medium
supplemented with 2% FBS, with and without the addition
of purified rPEDF and bevacizumab at concentrations of
100 ng/mL and 250 𝜇g/mL, respectively. The lower chamber
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was filled withminimal ECGmedium supplemented with 2%
FBS, with and without the addition of 50 ng/mL VEGF. After
8 hours at 37∘C in a humidified atmosphere of 95% air and 5%
CO
2
, the membranes were fixed in formalin and stained with
DAPI. Cells remaining on the upper side of the filter were
removed by gently wiping with a cotton swab and allowing
the filter to air dry.
2.10. Animal Experiments. All animal experiments were per-
formed in accordance with the ARVO declaration for the
use of animals in ophthalmic research and in accordance
with the German Law for the Protection of Animals, after
approval was obtained by the regulatory authorities. Rats
were anesthetized by an intraperitoneal injection of a mix-
ture of ketamine (75mg/kg; Ceva Tiergesundheit GmbH,
Du¨sseldorf, Germany) and xylazine (10mg/kg; Medistar
Arzneimittelvertrieb GmbH, Ascheberg, Germany). 32 male,
8-week-old Long Evans rats, weighing approximately 300 g,
were used for quantification of rPEDF after injection. They
were divided into two groups: one was transplanted with
Venus-transfected RPE cells and one was transplanted with
PEDF-transfected rat RPE cells.
2.11. Laser-Induced CNV. CNV was generated by laser-
induced rupture of Bruch’s membrane in 40 male, 8-week-
old Long Evans rats, weighing approximately 300 g. Briefly,
rats were anesthetized and pupils were dilated with phenyle-
phrine hydrochloride (2.5%) and tropicamide (0.5%). With a
coverslip used as a contact lens, 6 argon laser spots (150mW
intensity, 100ms duration, and 50 𝜇m size; Carl ZeissMeditec
AG, Jena, Germany) were delivered to the retina and choroid
of the right eye of each rat. Production of a bubble at the
time of laser exposure as indication of correct focusing was
noted and only these laser spotswere included in the study. To
investigate the effect of cell transplantation on laser-induced
CNV, the laser-treated rats were randomized into 4 groups
of 10 rats each: one group was transplanted subretinally with
PEDF-transfected rat RPE cells, one group was transplanted
with Venus-transfected RPE cells, one group was injected
subretinally with a volume of PBS equal to the volume
of cells, and one group served as the noninjected control.
Eight additional rats were used for choroidal flat-mount
preparations 8 weeks after laser-induced CNV. Transfected
RPE cells were suspended in PBS at a density of 5 × 103
cells/𝜇L; 2𝜇L was injected into the subretinal space of the
right eye between the host RPE and photoreceptor cell layers,
using a de Juan cannula (Bausch + Lomb, Rochester, NY)
attached to a 10 𝜇L Hamilton syringe (HamiltonMesstechnik
GmbH, Ho¨chst, Germany). Prior to cell transplantation, a
channel leading to the subretinal space was generated using a
30-gauge cannula. Sham injections containing an equivalent
volume of PBS were injected into the dorsal subretinal space
in an identical manner.
2.12. Fluorescein Angiography. Fluorescein angiography was
performed in anesthetized rats at days 7 and 14 after laser
photocoagulation using the Retina Angiograph II imaging
system (Heidelberg Engineering GmbH, Heidelberg, Ger-
many). After intraperitoneal injection of 1mL of 2.5% sodium
fluorescein, angiograms were obtained at 0-1 minute (early
phase) and 8-9 minutes (late phase) after injection. Grade
of CNV was estimated by a blinded observer that examined
fluorescein leakage on the angiograms, according to the
following criteria: grade 0 (no fluorescein leakage), grade
1 (very mild leakage or staining), and grade 2 (fluorescein
leakage indicating CNV).
2.13. Evaluation of Choroidal Neovascularization on Flat-
Mounts. Eyes were enucleated at 2 and 8 weeks and fixed
in 2% paraformaldehyde for 4 hours at room temperature.
The RPE-choroid-sclera complex was isolated and, after
permeabilization with 1% Triton X-100 in PBS for 1 hour at
room temperature, incubated at 4∘C with FITC-conjugated
isolectin B4 (1 : 50; Sigma-Aldrich), which labels endothelial
cells. After overnight incubation, the RPE-choroid-sclera
complex was washed with PBS and mounted on glass slides,
using Mowiol (Carl Roth GmbH, Karlsruhe, Germany),
examined by fluorescence microscopy, photographed, and
analyzed with ImageJ software.
2.14. Statistical Analysis. Statistical analysis of all experiments
was performed using one-wayANOVAwithDunnett’smulti-
ple comparison test (GraphPad Prism 5; GraphPad Software,
La Jolla, CA).
3. Results
3.1. PEDF Sequence Homology. Sequence analysis of the
recombinant PEDF showed an 87.7% and 80.9% homology
with bovine and rat PEDF, respectively. The two functional
epitopes, which are responsible for the antiangiogenic and
neurotrophic activity of PEDF [50], showed a 93.6% homol-
ogy with bovine PEDF and an 84.6% homology with rat
PEDF, indicating that the recombinant human PEDF used in
our studies would bind to the PEDF receptor on human as
well as bovine and rat cells.
3.2. PEDF Secretion by Immortalized Rat RPE Cells. Isolated
rat RPE cells exhibited the typical cobblestone morphology
and pigmentation (Figure 1(a)). Immortalized rat RPE cells,
obtained by transfection of primary cells with the pSV3-neo
plasmid, were no longer pigmented but showed the same
epithelial morphology as ARPE-19 cells (Figures 1(b) and
1(c)). The immortalized rat RPE cells became easily trans-
fected and survived after transplantation to the subretinal
space of rats for the 3 months the cells have been observed
(Figures 1(d)–1(g)). Immortalized rat RPE cells, cotransfected
with SB100X transposase and pT2-CMV-PEDF/EGFP trans-
poson plasmids, expressed and secreted recombinant human
PEDF. To obtain cells that secreted identical levels of PEDF,
single transfected cells were selected and expanded by further
cultivation.The clonewhichwas used for further experiments
secreted 2 ng PEDF/104 cells/day, as analyzed by ELISA and
immunoblotting (Figure 2(a)); the highest secretion level
was reached 1 week after transfection and remained constant
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Figure 1: Morphology and localization of immortalized rat RPE cells. Primary rat RPE cells (a) were immortalized by transfection with
pSV3-neo plasmid DNA. In vitro immortalized cells (b) were no longer pigmented but exhibited the same morphology as ARPE-19 cells
(c). Cryosections of rat retinas at one day after transplantation (d) showed that the transplanted fluorescent cells transfected with the pT2-
CAGGS-Venus transposon plasmid were localized adjacent to the RPE layer; by one week after transplantation (e) the cells appeared to have
migrated away from the transplantation site (transfected cells∗, RPE∗∗, and choroid∗∗∗). A retinal flat-mount preparation (f) shows a cluster of
transplanted fluorescent cells one week after transplantation. Fundus angiography illustrates the transplanted cells (fluorescence) at 3 months
(g) after subretinal transplantation (scale bars: 200 𝜇m for (a); 500 𝜇m for (b)–(f); 200𝜇m for (g); selected areas of (a)–(f) are 2x the original
magnification).
throughout the 10 passages the cells have been followed in
culture.
3.3. Quantification of rPEDF in Rat Eyes after Transplantation.
Based on the level of PEDF secreted by the transfected rat RPE
cells, we estimated the number of cells necessary to achieve an
optimal therapeutic effect when transplanted subretinally in
a rat model of choroidal neovascularization.The level of total
PEDF was determined by Western blot analysis in rat eyes
transplantedwith PEDF-transfected rat RPE cells at day 1, at 1,
2, and 3 weeks after subretinal transplantation. Compared to
control eyes, a 2-fold increase in total PEDF was reached by
the first week and remained constant during the 3 weeks of
follow-up (Figure 2(b)). The amount of recombinant PEDF
per transplanted rat eye remained constant at 0.72–0.84 ng
during the 4 weeks of follow-up, as determined by ELISA
using Ni-NTA HisSorb plates (Figure 2(c)). Recombinant
human PEDF was purified with Ni-NTA resin from con-
ditioned medium of either PEDF-transfected ARPE-19 or
PEDF-transfected rat RPE cells (Figure 2(d)).
3.4. Neurite Outgrowth and Reduced Photoreceptor Degenera-
tion. Purified recombinant PEDF induced neurite outgrowth
in the SH-SY5Y human neuroblastoma cell line formingwell-
branched structures (Figure 3(a)). Compared to nontreated
controls, the neurite length, normalized to the area of
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Figure 2: PEDF secretion by immortalized RPE cells in vitro and in vivo. (a) ELISA-based quantification and Western blot analysis of total
PEDF secretion by immortalized rat RPE cells in vitro at passages 1, 2, 5, and 10 (grey bars) after SB100X-mediated transfection with the pT2-
CMV-PEDF/EGFP transposon plasmid. Note that nontransfected control cells secreted only very small amounts of endogenous PEDF (white
bar). Data represent the mean ± SD from 2 independent measurements (∗∗∗𝑝 = 0.0001). (b) Western blot analysis of total PEDF extracted
from rat control eyes and eyes at 1 day, 1, 2, and 3 weeks after subretinal transplantation of PEDF-transfected rat RPE cells. Double bands
indicated the slightly different molecular weights of endogenous (46.5 kDa) and recombinant human PEDF (47.5 kDa), which included a His-
tag. Loading of equal protein amounts was confirmed by similar densities of GAPDHprotein bands (36 kDa). Note that for these experiments
the number of cells transplanted was 1 × 105, since the low sensitivity of the anti-PEDF antibodies required a larger amount of protein. Data
represent the mean ± SD from 2 independent measurements. (c) ELISA-based quantification of recombinant PEDF secretion in vivo in
lysates of rat eyes at 1 day, 1, 2, 3, and 4 weeks after subretinal transplantation of 1 × 104 PEDF-transfected RPE cells, showed a constant
level of recombinant human PEDF. For nontransfected control cells recombinant PEDF was not detectable (left bar), because the analysis
was carried out with Ni-NTA HisSorb plates. Each bar represents the average data of three injected eyes (∗∗∗∗𝑝 < 0.0001). (d) Coomassie
blue-stained SDS-PAGE showed the Ni-NTA purified recombinant human PEDF, secreted by transfected ARPE-19 or immortalized rat RPE
cells. Noncomplete saturation of the Ni-NTA bindings sites by rPEDF led to the copurification of a small amount of bovine serum albumin
(light band at ∼60 kDa), a component of the cell culture medium.
the SH-SY5Y cell bodies, increased by 3.12 ± 1.09- and
6.14 ± 1.58-fold in the presence of 20 and 100 ng/mL rPEDF,
respectively (Figure 3(b)). In organotypic cultures of bovine
neural retinas, addition of recombinant PEDF protected the
photoreceptor cell outer segments from degeneration, as
visualized by hematoxylin/eosin and immunohistochemical
staining (Figure 3(c)). At 72 hours after cultivation, the
number of nuclei in the ganglion cell layer (GCL), the inner
nuclear layer (INL), and the outer nuclear layer (ONL) was
reduced to 63.3%, 60.0%, and 86.5%, respectively. However,
supplementation with 100 ng/mL rPEDF protected the cell
nuclei in all layers with only a decrease of 1.10% in the GCL
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Figure 3: Neurogenic activity of purified recombinant PEDF. (a) 5 days after the addition of 20 and 100 ng/mL of rPEDF, it was evident that
rPEDF stimulated neurite outgrowth (scale bar: 50 𝜇m). (b) Quantification showed a 3-fold increase of neurite outgrowth in the presence
of 20 ng/mL rPEDF and a 6-fold increase in the presence of 100 ng/mL rPEDF. Data represents the mean ± SD of measurements from 6
microscopic fields from 2 independent experiments (∗∗∗∗𝑝 < 0.0001; one-way ANOVA with Dunnett’s multiple comparison test; control
versus 20 and 100 ng/mL rPEDF). Values were normalized to the mean value of the control cultures. (c) Cultivated retinas in the presence
of 0 and 100 ng/mL purified rPEDF showed that in the presence of rPEDF the loss of photoreceptors, as visualized with anti-rhodopsin
antibodies (red), was significantly less than in control cultures. (d) Quantification of cell nuclei, visualized by staining with DAPI, in the
ganglion cell layer (GCL) and the inner (INL) and the outer (ONL) nuclear layer, showed that the number of cells was the same in freshly
isolated retinas and retinas treated with rPEDF. Data are presented as mean ± SD of the average number from 3 different sections. Statistical
analysis showed significant differences between control and rPEDF-treated retinas as well as between control and freshly isolated retinas in
the GCL (∗∗∗𝑝 = 0.0002), the INL (∗∗∗𝑝 = 0.0003), and the ONL (∗∗𝑝 = 0.0063).
and 2.92% in the INL compared to freshly isolated retinas;
the number of cell nuclei in the ONL was slightly increased
(Figure 3(d)).
3.5. Inhibition of Angiogenic HUVEC Sprouting by Purified
rPEDF. The addition of VEGF to HUVEC spheroids elicited
the formation of sprouts, whichwas inhibited by recombinant
PEDF and bevacizumab (Figure 4(a)). Compared to control,
20 ng/mL of VEGF increased cumulative sprout length 3.1
times. Sprouting was reduced by the anti-VEGF monoclonal
antibody bevacizumab by 36%, 68%, and 75% at concentra-
tions of 50, 250, and 500 𝜇g/mL, respectively. The addition of
purified recombinant PEDF reduced VEGF-induced sprout-
ing by 47%, 56%, and 68% at concentrations of 20, 100, and
200 ng/mL, respectively (Figure 4(b)). The cocultivation of
spheroids with PEDF-transfected ARPE-19 cells resulted in
the inhibition of HUVEC sprouting by 50%, compared to
spheroids cultivated in the presence of nontransfectedARPE-
19 cells (Figure 4(c)).
3.6. Enhanced Apoptosis by Purified rPEDF. In medium con-
taining 0.2% fetal bovine serum (FBS), 20.1% of HUVEC was
apoptotic. Supplementation with 20 ng/mL of VEGF reduced
the number of apoptotic cells to 9.53%, whereas the addition
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Figure 4: Inhibition of HUVEC sprouting by recombinant PEDF. (a) Exemplary fluorescencemicrographs of DiO labeledHUVEC spheroids
cultured in the presence of 2% serum, VEGF, VEGF plus rPEDF, and VEGF plus bevacizumab (scale bars: 50 𝜇m). (b) Effect of rPEDF and
bevacizumab on VEGF-stimulated sprouting of human umbilical vein endothelial cells (HUVEC) spheroids. VEGF increased the cumulative
sprouting length bymore than 60%above control.The addition of rPEDF at a concentration of 200 ng/mL reduced sprouting below the control
level. To achieve the same level of inhibition as 200 ng/mL of rPEDF, it required 250𝜇g/mL of bevacizumab. The differences between VEGF-
inducedHUVEC sprouting and all concentrations of rPEDF and bevacizumabwere statistically significant (∗∗∗∗𝑝 < 0.0001; one-wayANOVA
with Dunnett’s multiple comparison test; VEGF versus VEGF + recombinant PEDF and VEGF + bevacizumab).Themean cumulative sprout
length per spheroid was calculated by measuring and averaging the length of all sprouts from 10 randomly selected spheroids. (c) Cultures of
HUVEC spheroids in the presence of 150,000 nontransfected ARPE-19 cells and 20 ng/mL VEGF (white bar) showed significant sprouting,
whereas, in the presence of 150,000 transfected ARPE-19 cells producing 30 ng rPEDF/day (grey bar), sprouting was reduced by 50% (∗∗∗∗𝑝 <
0.0001).
of 100 ng/mL rPEDF or 250𝜇g/𝜇L bevacizumab increased
apoptosis to 32.7% and 20.9%, respectively (Figure 5). In
endothelial cell growth (ECG) medium containing 10% FBS,
only 5.05% of HUVEC was apoptotic and the addition of
100 ng/mL rPEDF and 250 𝜇g/mL bevacizumab increased the
number of apoptotic cells to 27.2% and 17.0%, respectively
(Figure 5).
3.7. Inhibition of Cell Migration by rPEDF. Migration of
endothelial cells is an essential step in the process of blood
vessel growth and VEGF acts as a potent activator of HUVEC
migration. Spontaneousmigration byHUVECwas low, 74.2±
9.82 cells/field migrated across the filter. However, in the
presence of 50 ng/mL VEGF the number of migrated cells
increased to 229.6 ± 29.22 cells/field, whereas the addition of
100 ng/mL recombinant PEDF and 250 𝜇g/mL bevacizumab
reduced VEGF-stimulated HUVEC migration to 53.6 ± 7.53
and 90.8 ± 10.5 cells/field, respectively (Figure 6).
3.8. Effect of rPEDF Secreted by Transfected Rat RPE Cells
on Laser-Induced CNVLesions. Fluorescein angiographywas
carried out to analyze the grade of CNV leakage in rat eyes
transplanted subretinally with 1 × 104 PEDF-transfected rat
RPE cells, secreting approximately 2 ng PEDF/day, as well as
in eyes transplanted withVenus-expressing cells, noninjected
eyes, and sham-injected eyes. Representative angiograms
were taken 1 and 2 weeks after laser treatment (Figure 7(a)).
In rat eyes transplanted with PEDF-transfected rat RPE
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Figure 5: Effect of recombinant PEDF on apoptosis of HUVEC.
The addition of VEGF protected HUVEC from apoptosis induced
by low serum. Apoptosis of HUVEC was significantly increased
by the addition of rPEDF or bevacizumab (∗∗∗∗𝑝 < 0.0001; one-
way ANOVA with Dunnett’s multiple comparison test; VEGF/ECG
medium versus VEGF/ECG medium + rPEDF and bevacizumab).
Data are presented as mean ± SD of the average apoptotic cell
number from at least 6 micrographs.
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Figure 6: Effect of recombinant PEDF on migration of HUVEC.
Quantitative analysis showed that migration of HUVEC was stim-
ulated by VEGF and that VEGF-stimulated migration was signifi-
cantly inhibited by rPEDF and bevacizumab (∗∗∗∗𝑝 < 0.0001; one-
way ANOVAwithDunnett’s multiple comparison test; VEGF versus
VEGF + rPEDF and bevacizumab). Cells of 10 randomly selected
microscopic fields were enumerated and presented as mean ± SD.
cells, lesion development clearly showed reduced fluorescein
leakage at both 1 and 2 weeks after laser treatment. At days
7 and 14 after laser treatment, the incidence of grades 0,
1, and 2 lesions was similar in noninjected eyes and eyes
transplanted with Venus-transfected cells. In sham-injected
eyes, grade 2 lesions were reduced by 24.3% and grade 1
lesions increased by 50.8% at day 7 after laser treatment; after
14 days, the number of grade 2 lesions increased slightly to
26.5%, whereas the number of grade 1 lesions did not change.
In PEDF-treated eyes, a reduction in grade 2 lesions of 78.2%
and 43.1% was observed after 7 and 14 days, respectively
(Figure 7(b)). Detailed statistical analysis of the clinically
relevant grade 2 lesions revealed that the differences between
noninjected, sham-injected, and control-transplanted eyes
and eyes transplanted with PEDF-transfected cells were
significant both at week 1 (∗𝑝 = 0.042) and at week 2 (∗∗𝑝 =
0.0023) (Figure 7(c)).
3.9. rPEDF-Mediated Reduction of CNV Area Measured
on Choroidal Flat-Mounts. Analysis of isolectin B4 stained
choroidal flat-mounts, prepared 2 weeks after laser treatment
and subretinal transplantation of PEDF-transfected rat RPE
cells, showed that theCNV lesion areawas reduced compared
to noninjected control eyes (Figure 8(a)). The area of CNV
in eyes transplanted with PEDF-transfected rat RPE cells was
46.1% of the area of CNV in eyes injectedwith PBS; the area of
CNV in noninjected eyes and eyes transplanted with Venus-
expressing cells was 88.8% and 87.2% of the area of PBS-
injected eyes, respectively. Statistical analysis showed that the
differences between eyes transplantedwith PEDF-transfected
rat RPE cells and all other groups were significant, with a 𝑝
value of less than 0.05 (Figure 8(b)). A comparison of the
CNV area at 8 weeks after laser treatment showed a reduction
of 47.5% in eyes transplanted with PEDF-transfected rat RPE
cells compared to eyes transplanted with Venus-transfected
cells (Figure 8(c)).
4. Discussion
The retinal pigment epithelium maintains the avascular-
ity of the retina and a healthy choroidal vasculature by
expressing and maintaining a balance between angiogenic
and antiangiogenic factors, in particular VEGF and PEDF.
The evidence that in neovascular AMD the equilibrium is
shifted in favor of the angiogenic VEGF [51, 52] led to
the development of inhibitors of VEGF, for example, the
humanized monoclonal antibody bevacizumab (Avastin),
its Fab fragment ranibizumab (Lucentis), and aflibercept
(Eylea), which engendered a new era for the treatment of
neovascular AMD and other ocular neovascular diseases
[53–55]. We theorized that the side effects, resulting from
frequent intravitreal injections of anti-VEGF antibodies to
prevent CNV, could be alleviated by subretinal transplan-
tation of genetically modified pigment epithelial cells that
continuously secrete antiangiogenic PEDF. Autologous pig-
ment epithelial cells transplanted to the subretinal space in
neovascular AMD patients [28, 29] were well tolerated over
a long period of time. However, no significant beneficial
effects have been shown on vision. We postulate that vision
improvement requires the inhibition of neovascularization
by higher levels of PEDF. To insure that the transplanted
cells secrete continuously a sufficient quantity of recombinant
PEDF, we have developed an efficient nonviral transfection
protocol, based on the Sleeping Beauty (SB100X) transposon
system, and have shown that recombinant PEDF secretion in
culture by PEDF-transfected cells was stable and constant for
more than 1 year [41].
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Figure 7: Effects of subretinal transplantation of RPE cells transfected with the PEDF gene on laser-induced CNV in a rat model. (a)
Fluorescein angiograms of rat eyes 1 and 2 weeks after laser injury and cell transplantation showed the decrease in leakage in eyes transplanted
with transfected RPE cells secreting 2 ng rPEDF/day, but not in eyes transplanted with Venus-expressing cells or sham-operated eyes. (b)
Distribution of total CNV lesions, classified by a blinded observer into grade 0 (no leakage), grade 1 (very mild leakage), and grade 2
(clear leakage), showed that the eyes transplanted with PEDF-transfected cells had fewer grade 2 lesions than the other groups. Each group
comprised at least 6 animals. (c) Quantification of clinically relevant grade 2 CNV lesions in rat eyes after 1 and 2 weeks showed that eyes
transplanted with rPEDF-expressing cells had significantly fewer grade 2 lesions (1 week: ∗𝑝 = 0.042; 2 weeks: ∗∗𝑝 = 0.0023). (d) Exemplary
fluorescein angiograms of grades 0, 1, and 2 lesions.
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Figure 8: Choroidal flat-mounts of retinas from a rat model of laser-induced CNV. (a) Exemplary fluorescence micrographs of isolectin B4
(vascular leakage) stained choroidal flat-mounts 2 weeks after laser treatment. Note the decrease in B4 staining in the retinas transplanted
with RPE cells transfected with the PEDF gene secreting 2 ng rPEDF/day. (b) Quantitative analysis of area of vascular leakage 2 weeks after
laser injury showed that transplantation of PEDF-transfected RPE cells reduced the area of leakage by over 50% compared to control, sham-
operated eyes, and eyes transplanted with Venus-expressing cells (∗∗𝑝 = 0.0012, rPEDF versus no injection, sham injection, and Venus-
expressing cells). (c) Choroidal flat-mounts of rat eyes 8 weeks after laser injury showed that the reduction in leakage observed at 2 weeks
in eyes transplanted with PEDF-transfected RPE cells was still approximately 50% of the leakage in eyes transplanted with Venus-expressing
cells (∗∗𝑝 = 0.0022).
PEDF is a multifunctional protein that exhibits varied
cellular actions, indicating that there are distinctive receptors
that elicit diverse events. In fact, the two functional epitopes
identified, a 34-mer peptide (residues 24–57) and a 44-
mer peptide (residues 58–101) [50], appear to bind to two
different receptors: the 44-mer peptide binds to a 80 kDa
protein found in retinoblastoma Y-79 cells, neuronal cells,
and retinal cells [56, 57] and induces neuroblastoma cell
differentiation but does not prevent vascular leakage, whereas
the 34-mer peptide binds to a 60 kDa receptor on endothelial
cells [58] and prevents vascular leakage, suppresses new
but not established blood vessels, and has no effect on
retinoblastoma cells. Since the ultimate goal of transplanting
PEDF-transfected pigment epithelial cells subretinally is for
the cells to secrete active PEDF to inhibit CNV, it is critical
that the recombinant PEDF secreted by the transfected cells
is fully functional. In this study, we analyzed the functionality
of purified recombinant human PEDF secreted by ARPE-19
and rat RPE cells transfected with the PEDF gene using the
SB100X transposon system. Affinity-purified recombinant
PEDF showed neurotrophic activity, as evidenced by the
differentiation of human neuroblastoma cells in culture
and protection of photoreceptor cells from degeneration in
organ cultures of neural retinas. In vitro, the antiangiogenic
properties of recombinant PEDF were confirmed by the
inhibition of VEGF-stimulated sprouting and chemotaxis:
rPEDF, secreted by RPE cells transfected using the SB100X
transposon, is a potent inhibitor of HUVEC sprouting, the
inhibition is concentration dependent, and the inhibitory
activity is approximately 2000 times more potent than the
activity of bevacizumab.
The ultimate goal of transplanting pigment epithelial
cells to the subretinal space is to populate the subretinal
space with PEDF-transfected cells that continuously secrete
rPEDF for the treatment of retinal degenerative diseases,
such as neovascular AMD. Here we have shown that it is
12 BioMed Research International
possible to inhibit CNV by transplanting pigment epithelial
cells transfected with the PEDF gene that express constant
elevated levels of PEDF, as evidenced by the suppression of
the development of laser-induced CNV lesions by transplan-
tation of PEDF-transfected rat RPE cells into the subretinal
space of Long Evans rats. Rats transplanted with 1 × 104 RPE
cells secreting 2 ng rPEDF/day inhibited the development of
clinically relevant grade 2 lesions by 78% and 43% after 1 and 2
weeks, respectively. Transplantation into the subretinal space
of rats of 1 × 104 rat RPE cells, expressing 2 ng rPEDF/day in
vitro, resulted in a constant level of rPEDF of 0.72–0.84 ng
rPEDF in the eye indicating that the subretinal environment
supports the expression of the PEDF gene integrated into the
RPE cell’s genome. To our knowledge, this study indicates for
the first time the concentration of PEDF that is necessary to
suppress CNV in vivo. A study using virally transduced cells
for transplantation in Royal College of Surgeons (RCS) rats
analyzed the production of PEDF in vitro but not the amount
actually present in vivo [59].
A critical consideration for the treatment of neovascular
AMD with transplantation of PEDF-transfected cells is the
amount of PEDF produced, since too little PEDF will have
no effect and too much PEDF may result in receptor down-
regulation and an increase in neovascularization [60]. Our
laboratory is now in the process of investigating the optimal
level of secreted PEDF as well as its lower and upper limits
that will have a significant effect in vivo.
5. Conclusions
The results demonstrate that SB100X-transfected pigment
epithelial cells secrete constant levels of rPEDF. Homologous
PEDF-transfected rat RPE cells transplanted to the subretinal
space prevent development of severe CNV lesions and limit
the area of neovascularization in a rat model of CNV. Since
SB100X-mediated transfection integrates the transgene and
since RPE cells survive in the subretinal space, autologous
SB100X-mediated PEDF-transfected cells transplanted to the
subretinal space of neovascular AMD patients should secrete
recombinant PEDF and inhibit CNV for the life of the
patients.
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